Skip to main content
SpringerLink
Log in

Does everyone develop covert cancer?

  • Comment
  • Published:

From Nature Reviews Cancer

View current issue Sign up to alerts

Do we all develop a covert cancer as we age?

Abstract

Around one in three individuals, if they live long enough, will have a confirmed clinical diagnosis of overt cancer, and there is increasing evidence that many of us — I contend all of us — develop covert cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sakr, W. A. et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J. Urol. 150, 379–385 (1993).

    Article  CAS  PubMed  Google Scholar 

  2. Welch, H. G. & Black, W. C. Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann. Int. Med. 127, 1023–1028 (1997).

    Article  CAS  PubMed  Google Scholar 

  3. Mori, H. et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc. Natl Acad. Sci. USA 99, 8242–8247 (2002).

    Article  CAS  Google Scholar 

  4. Ståhl, P. L. et al. Sun-induced nonsynonymous p53 mutations are extensively accumulated and tolerated in normal appearing human skin. J. Invest. Dermatol. 131, 504–508 (2011).

    Article  PubMed  Google Scholar 

  5. Welch, J. S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264–278 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Greaves, M. Darwinian medicine: a case for cancer. Nature Rev. Cancer 7, 213–221 (2007).

    Article  CAS  Google Scholar 

  7. Bissell, M. J. & Hines, W. C. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nature Med. 17, 320–329 (2011).

    Article  CAS  PubMed  Google Scholar 

  8. Esserman, L. J., Thompson, I. M. Jr & Reid, B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. J. Am. Med. Assoc. 310, 797–798 (2013).

    Article  CAS  Google Scholar 

  9. Maley, C. C. et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nature Genet. 38, 468–473 (2006).

    Article  CAS  PubMed  Google Scholar 

  10. Kostadinov, R. L. et al. NSAIDs modulate clonal evolution in Barrett's esophagus. PLoS Genet. 9, e1003553 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Evolution and Cancer, The Institute of Cancer Research, Brookes Lawley Building, 15 Cotswold Road, Sutton, SM2 5NG, Surrey, UK

    Mel Greaves

Authors
  1. Mel Greaves
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mel Greaves.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Greaves, M. Does everyone develop covert cancer?. Nat Rev Cancer 14, 209–210 (2014). https://doi.org/10.1038/nrc3703

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrc3703

  • Springer Nature Limited

This article is cited by

Search

Navigation